ID   NCI-H2369
AC   CVCL_A532
SY   H2369; H-2369
DR   EFO; EFO_0006678
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471012
DR   CCLE; H2369_PLEURA
DR   Cell_Model_Passport; SIDM00104
DR   Cosmic; 1995411
DR   Cosmic-CLP; 1290808
DR   DepMap; ACH-002123
DR   GDSC; 1290808
DR   GEO; GSM1669818
DR   PharmacoDB; NCIH2369_1088_2019
DR   Wikidata; Q54907968
RX   PubMed=8806092;
RX   PubMed=11030152;
RX   PubMed=23830731;
RX   PubMed=25485619;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.75%; Native American=0%; East Asian, North=0.77%; East Asian, South=0.91%; South Asian=0%; European, North=67.35%; European, South=30.22% (PubMed=30894373).
ST   Source(s): Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 13
ST   D18S51: 13,15
ST   D21S11: 29
ST   D3S1358: 16
ST   D5S818: 10,12
ST   D7S820: 10
ST   D8S1179: 11,13
ST   FGA: 19,21
ST   Penta D: 14
ST   Penta E: 7,13
ST   TH01: 9
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C7376; Pleural malignant mesothelioma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 06-09-19; Version: 22
//
RX   PubMed=8806092; DOI=10.1002/jcb.240630505;
RA   Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P.,
RA   McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr.,
RA   Carney D.N., Minna J.D., Mulshine J.L.;
RT   "NCI-Navy Medical Oncology Branch cell line data base.";
RL   J. Cell. Biochem. 63 Suppl. 24:32-91(1996).
//
RX   PubMed=11030152; DOI=10.1038/sj.onc.1203815;
RA   Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.;
RT   "Protein expression of the RB-related gene family and SV40 large T
RT   antigen in mesothelioma and lung cancer.";
RL   Oncogene 19:4632-4639(2000).
//
RX   PubMed=23830731; DOI=10.1016/j.cancergen.2013.04.006;
RA   Klorin G., Rozenblum E., Glebov O.K., Walker R.L., Park Y.,
RA   Meltzer P.S., Kirsch I.R., Kaye F.J., Roschke A.V.;
RT   "Integrated high-resolution array CGH and SKY analysis of homozygous
RT   deletions and other genomic alterations present in malignant
RT   mesothelioma cell lines.";
RL   Cancer Genet. 206:191-205(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//